Evidence map›Paper›PMID 41399072›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2025

[Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease].

Jingwen Lan, Zhe Chen, Yongjing Cheng, Like Zhao

Abstract readEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingwen LanDepartment of Rheumatology and Immunology, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhe ChenDepartment of Rheumatology and Immunology, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Yongjing ChengDepartment of Rheumatology and Immunology, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Like ZhaoDepartment of Rheumatology and Immunology, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the clinical characteristics, treatment regimens, and the efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease (CTD-ILD).

methodsThis single-center retrospective cohort study enrolled 129 elderly patients (≥60 years) with a confirmed diagnosis of CTD-ILD at Beijing Hospital from June 2016 to June 2024. Baseline data, including comorbidities and CTD subtypes, treatment regimens (glucocorticoids, immunosuppressants, antifibrotic agents), pulmonary function parameters, high-resolution computed tomography (HRCT) imaging features, and adverse events were retrieved from the electronic medical record system. Treatment efficacy was evaluated according to the 2022 American Thoracic Society/European Respiratory Society criteria for progressive pulmonary fibrosis. Statistical analyses were performed using SPSS 26.0, with

results(1) Clinical characteristics: The predominant CTD subtypes were rheumatoid arthritis (RA), primary Sjögren syndrome (pSS), and polymyositis or dermatomyositis (PM/DM). Hypertension was present in 45.7% of the patients, reflecting the characteristics of multiple comorbidities in the elderly population. (2) CTD treatment regimens: 76.0% of the patients received glucocorticoid therapy, 83.7% used immunosuppressants (IS)/conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), among which cyclophosphamide had the highest usage rate (47.3%); 31.8% of the patients were combined with antifibrotic drugs (nintedanib 16.3%, pirfenidone 10.1%, and 5.4% used both). (3) Efficacy of antifibrotic therapy: There was no statistically significant difference in the 6-month HRCT progression rate between the antifibrotic and non-antifibrotic groups (31.3%

conclusionThe main subtypes of CTD-ILD in the elderly are RA, pSS, and PM/DM, which are often complicated with hypertension. Antifibrotic agents may significantly delay the deterioration of pulmonary function, but attention should be paid to the risks of gastrointestinal adverse effects and hepatotoxicity. Infection remains the primary complication, emphasizing the need to balance benefits of immunosuppressive therapy and the risk of infection to formulate treatment strategies.

Indexed as

Antifibrotic AgentsConnective Tissue DiseasesLung Diseases, InterstitialAgedAged, 80 and overFemaleGlucocorticoidsHumansImmunosuppressive AgentsIndolesMaleMiddle AgedPyridonesRetrospective StudiesTomography, X-Ray ComputedTreatment OutcomeAntifibrotic AgentsGlucocorticoidsImmunosuppressive AgentsIndolesnintedanibpirfenidonePyridonesAntifibrotic agentsConnective tissue disease-associated interstitial lung diseaseElderly

Identifiers

PMID41399072
PMCPMC12711420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.